Cranberry A-type PACs don't kill bacteria.
They prevent uropathogenic E. coli from attaching to bladder walls by inhibiting P-fimbriae adhesion.
This is a fundamentally different mechanism from antibiotics , it doesn't create resistance, it prevents colonization.
The mechanism is so specific that there's a validated dose-response: 36mg PAC-A/day is the threshold. Below that, nothing happens. Above it, significant UTI reduction. This is pharma-level mechanism specificity in a berry.
Publications of interest:
https://pubmed.ncbi.nlm.nih.gov/16055161/
https://pmc.ncbi.nlm.nih.gov/articles/PMC2873556/
https://pubmed.ncbi.nlm.nih.gov/10872208/